pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,661 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1846Endpoints1427Fierce Biotech749BioSpace739BioPharma Dive542raps245onclive165fda recalls
therapy area
allOncology12760Rare Disease3302Immunology2968Cardiology2834Hematology2273Pulmonology2221Vaccines
  • Sellas cancer vaccine cuts death risk by 41% in late-stage AML trial
    Sellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
    BioSpace · 1h agoPositive readoutPositive↗ source
  • Roche secures FDA approval for giredestrant, its first SERD for advanced breast cancer
    Roche announced that its experimental breast cancer drug giredestrant received FDA approval for treatment of patients with late‑stage disease. The approval places Roche into the selective estrogen…
    Endpoints · 3h agoApprovalPositive↗ source
← prev
page 1 of 227
next →
117
fda medwatch113
globenewswire health73
fda press59
1823
Psychiatry & CNS1227
Ophthalmology1125
Endocrinology & Metabolism794
Pain785
Nephrology768
  • Isomorphic Labs secures $5 billion Series C, doubling its recent $2.1 billion raise
    Isomorphic Labs, an AI‑driven drug discovery startup spun out of DeepMind, announced a $5 billion Series C financing, marking its second multibillion‑dollar round within six months. The funding fo…
    Fierce Biotech · 7h agoDealPositive↗ source
  • Eli Lilly inks $5.9 billion partnership with Stipple Bio to develop precision oncology drugs
    Eli Lilly has announced a partnership with Stipple Bio that could be worth up to $5.9 billion. The collaboration will focus on oncology drug candidates designed to target tumor cells more precisely…
    Fierce Biotech · 12h agoDealPositive↗ source
  • AriBio's AR1001 shows 31% slower cognitive decline in monotherapy Phase 3 trial
    AriBio presented data at the 2026 Clinical Trials on Alzheimer's Disease conference indicating its candidate AR1001 slowed cognitive decline compared with placebo in patients not taking other Alzhe…
    BioSpace · 1h agoPositive readoutPositive↗ source
  • FDA approves Roche's new breast cancer drug, poised to become its top-selling product
    The U.S. Food and Drug Administration has granted approval to a new breast cancer therapy developed by Roche. This clearance paves the way for the drug's market launch. Roche says the medication c…
    STAT · 1h agoApprovalPositive↗ source
  • Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trial
    Sellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…
    STAT · 3h agoPositive readoutPositive↗ source
  • Genetix Biotherapeutics reports $327M YTD sales and projects $500M full-year revenue, marking profitability
    Genetix Biotherapeutics, the former bluebird bio, announced that it has become profitable, reporting $327 million in U.S. net sales year‑to‑date and forecasting total 2026 sales of about $500 milli…
    BioSpace · 3h agoEarningsPositive↗ source
  • Capsida proposes new monkey testing framework after fatal gene therapy trial for brain disease
    Researchers presented investigations into a patient death that occurred in a gene therapy trial for a brain disease, which had raised concerns in the field. While the exact cause of death was not…
    STAT · 6h agoNegative readoutNegative↗ source
  • Marrow Therapeutics raises $173M to develop bone-marrow-targeted gene therapies for blood disorders
    Marrow Therapeutics announced a $173 million financing round, combining a $53 million Series A led by founder Scion Life Sciences and venBio with a $120 million Series B led by OrbiMed. The compan…
    BioSpace · 3h agoDealPositive↗ source
  • Marrow Therapeutics secures $173 million to advance siRNA therapy for sickle cell, targeting CRISPR competition
    Marrow Therapeutics announced a $173 million financing round to fund development of its siRNA drug aimed at treating sickle cell disease. The funding comes after FDA approval of two gene therapies…
    Endpoints · 3h agoDealPositive↗ source
  • Marrow Therapeutics raises $173 million to develop infusion therapy for sickle cell disease
    Marrow Therapeutics was announced on Tuesday by biotech entrepreneur Romesh Subramanian. The new company aims to create an infusion therapy for sickle cell disease that matches the efficacy of gene…
    STAT · 3h agoDealPositive↗ source
  • Panelists say 2027 could be Europe’s breakout year for biotech investment
    Fierce Biotech hosted a panel during its London Life Sciences Week to debate whether Europe can boost its biopharma investment in 2027. The discussion came a day after venture capital firm Sofinno…
    Fierce Biotech · 9h agoPositive↗ source
  • Cardinal Health advises correction of Presource kits containing recalled BD Alaris infusion sets
    Cardinal Health has issued a correction notice for its Presource convenience kits that include BD Alaris pump infusion sets that were previously recalled. The FDA classifies this recall as the mos…
    fda medwatch · 10h agoCRLNegative↗ source
  • Flavored nicotine tablets launch, raising concerns over appeal to youth
    New flavored nicotine tablets that melt in the mouth have been introduced by tobacco companies in several markets. Products include Zyn Melts by Philip Morris International in the United Kingdom…
    STAT · 6h agoNegative↗ source
  • Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemia
    Marrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…
    BioPharma Dive · 3h agoDealPositive↗ source
  • b.well introduces safety tools for AI health chatbots
    b.well, a startup focusing on patient data, announced new tools aimed at improving safety of AI-driven health chatbots. The tools address concerns that large language models may mishandle personal…
    Endpoints · 1h agoPositive↗ source
  • John Powers III named permanent director of NIH's National Institute of Allergy and Infectious Diseases
    NIH's National Institute of Allergy and Infectious Diseases (NIAID) has finally filled its top leadership vacancy that has persisted since 2025. The institute had been led in an acting capacity by…
    STAT · 2h agoNeutral↗ source
  • Biotech boards see more women, but CEO roles remain largely male-dominated
    Women now occupy roughly 29% of biotech board seats, a notable rise from about one‑fifth a few years ago, according to the latest Bedford Group Transearch report. Despite that progress, female CEO…
    BioSpace · 10h agoNegative↗ source
  • RFK Jr. urges federal funding for faith-based addiction recovery centers, sparking expert concerns over medication access
    Health Secretary Robert F. Kennedy Jr. toured Sheepgate, a Christian addiction recovery center in Iowa, and said the model should receive federal funding. He highlighted the center as an example of…
    STAT · 6h agoRegulatoryNeutral↗ source
  • Zero-tolerance signs in hospitals may not curb staff violence, authors argue
    Hospitals across the United States now display signs telling patients and visitors that abusive language, disruptive conduct, or aggression will not be tolerated and may result in removal or police…
    STAT · 6h agoNegative↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 6m agoLayoffsNegative↗ source
  • Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
    A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.
    BioSpace · 1h ago↗ source
  • IQVIA report finds 90% of drugs launched 2016-2020 unlikely to recoup costs
    IQVIA analyzed 825 novel medicines launched in the United States between 1991 and 2020 and found that profitability has sharply declined over time. For drugs launched from 2016 to 2020, a positive…
    BioSpace · 1d agoNegative↗ source
  • J&J to acquire Ollin Biosciences for $2.2 billion to advance bispecific eye drug OLN324 against Roche’s Vabysmo
    Johnson & Johnson announced it will buy Ollin Biosciences for an upfront $2.2 billion, with additional regulatory and commercial milestones that could bring total payments to about $3.3 billion. O…
    Fierce Biotech · 1d agoDealPositive↗ source